BMO Capital Reiterates Market Perform Rating on Sarepta Therapeutics (SRPT)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
TD Cowen Reiterates Hold Rating on Sarepta Therapeutics (SRPT)
July 21, 2025 6:55 AM EDTTD Cowen analyst Ritu Baral reiterated a Hold rating and $28.00 price target on Sarepta Therapeutics (NASDAQ: SRPT)
The analyst comments "Lack of proactive disclosure in recent rh74 GTx-related death undermines credibility with investors. Last week, at the start of the International LGMD Conference (Orlando), unsubstantiated media reports disclosed a 51 yr old pt in the Ph1/2 trial of rh74-based GTx SRP-9004 (for LGMD Type 2D) died 11 wks post-Tx... More
BofA Securities Reiterates Neutral Rating on Sarepta Therapeutics (SRPT)
July 21, 2025 6:03 AM EDTBofA Securities analyst Tazeen Ahmad reiterated a Neutral rating and $20.00 price target on Sarepta Therapeutics (NASDAQ: SRPT).
The analyst comments "On Friday night, Sarepta (SRPT) reported that the company received an informal request from the Food and Drug Administration (FDA) to voluntarily halt all shipments of Elevidys. The company announced they plan... More
